As of 2018, there is no modifying therapy for AD [15], and only two families of medications are approved as palliatives for AD symptoms: the cholinesterase inhibitors and the N-methyl-D-aspartate receptor (NMDAR) antagonists, while various new drugs are under clinical trials evaluations, among them the promising new family of secretase inhibitors [16–18]. This evidence concerns the gene BCHE and Alzheimer disease.